Targeted Treatment of Brain Cancer: From Basic Research to Clinical Relevance in the Treatment of Glioma Patients
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 2568
Special Issue Editors
2. Department of Clinical Medicine, Aarhus University, Incuba Skejby, Building 2, Palle Juul-Jensens Boulevard 82, J618, DK8200 Aarhus, Denmark
Interests: glioma; tumor-treating fields; neurosurgical methods; neuron-to-brain tumor synapses
Special Issue Information
Dear Colleagues,
Malignant glioma is a devastating cancer with poor prognosis and no cure. The current treatment involves a combination of maximum safe resection, concurrent chemo/radiation, adjuvant chemotherapy, and tumor-treating fields. However, the median overall survival remains only 1–2 years depending on predictive molecular and clinical features. Recurrent disease has no effective treatments, highlighting a pressing need for significant advancements in both primary and recurrent glioma disease. In 2016, molecular analyses were included in the WHO diagnostic criteria for brain cancer and updated in 2021, with genomic profiling becoming a standard in many countries.
To address this critical need, the scientific journal Cancers is pleased to announce a Special Issue dedicated to targeted treatments and their evaluation methods for malignant glioma. This comprehensive overview will cover recent initiatives and research with a focus on translational and clinical relevance. Modalities such as tracer-specific imaging and imaging sequencing optimization, liquid biopsies with ctDNA, surgical procedures, individualized radiation therapy, biomarker-based and/or precision medical therapy, and real-world patient data collection will be explored. The issue will also include studies with negative results.
We invite basic and clinical researchers in the fields of imaging, surgery, oncology, radiation-oncology, pathology, and genomics to contribute their expertise to this important Special Issue. By sharing the latest research and developments, we hope to advance targeted treatments and improve outcomes for patients with malignant glioma.
Dr. Anders Rosendal Korshoej
Dr. Dorte Schou Nørøxe
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeted treatment
- personalized medicine
- glioma
- glioblastoma
- tumor heterogeneity
- tumor microenvironment
